Bruce Fireman to Product Surveillance, Postmarketing
This is a "connection" page, showing publications Bruce Fireman has written about Product Surveillance, Postmarketing.
Connection Strength
1.792
-
Two Authors Reply. Am J Epidemiol. 2016 Jan 15; 183(2):167-8.
Score: 0.498
-
Conducting prospective sequential surveillance in real-world dynamic distributed databases. Pharmacoepidemiol Drug Saf. 2020 10; 29(10):1331-1335.
Score: 0.169
-
Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. Diabetes Care. 2018 01; 41(1):39-48.
Score: 0.142
-
A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Am J Epidemiol. 2015 Apr 15; 181(8):608-18.
Score: 0.118
-
Targeted maximum likelihood estimation in safety analysis. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S91-8.
Score: 0.106
-
Safety of Zostavax™--a cohort study in a managed care organization. Vaccine. 2012 Oct 19; 30(47):6636-41.
Score: 0.099
-
Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol. 2012 Jun 01; 175(11):1100-9.
Score: 0.097
-
Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:32-40.
Score: 0.095
-
When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:50-61.
Score: 0.095
-
Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:62-71.
Score: 0.095
-
A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:282-90.
Score: 0.095
-
Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
Score: 0.093
-
Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004 Jun; 23(6):485-9.
Score: 0.056
-
Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2009 May; 28(5):438-40.
Score: 0.020
-
Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007 Sep; 26(9):771-7.
Score: 0.018